Prestige Consumer Healthcare reported second-quarter fiscal 2027 revenue of $336.3 million, a 22.7% increase year-over-year, driven by the Breathe Right and LaCorium acquisitions. Adjusted diluted EPS was $1.13, up from $1.07 in the prior year period. The company updated its full-year fiscal 2027 revenue guidance to $1,280-$1,290 million and adjusted diluted EPS guidance to $4.48-$4.55, citing production variability at the Pillar5 facility impacting Clear Eyes supply. Net debt stood at approximately $2 billion following recent acquisitions and refinancing activities. Prestige Consumer Healthcare is a leading consumer healthcare company that markets, sells, manufactures and distributes over-the-counter health products across global markets.
